Business
Helix BioPharma to Present L-DOS47 Lung Cancer Research Findings at Keystone Symposia Meeting in Lake Louise, Alberta
Helix BioPharma to Present L-DOS47 Lung Cancer Research Findings at Keystone Symposia Meeting in Lake Louise, Alberta.
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nAURORA, ON, Feb. 1 /CNW/ - Helix BioPharma Corp. ( TSX: HBP / Frankfurt:\nWKN 918864 )\n\n\nDr. Heman Chao, Vice President of Research at Helix BioPharma, a\ndeveloper of novel cancer therapeutics, will be presenting a scientific poster\non Friday, February 2nd at the Keystone Symposia meeting, \"Antibodies as\nDrugs: From Basic Biology to the Clinic\".\n\n\nThe poster entitled \"L-DOS47 a Lung Adenocarcinoma Specific\nImmuno-Conjugate\" highlights the specificity of Helix's L-DOS47\nimmuno-conjugate new drug product candidate in binding to human lung\nadenocarcinoma cells. L-DOS47 is the first immuno-conjugate therapeutic drug\nproduct candidate derived from Helix's novel anti-cancer DOS47 platform\ntechnology.\n\n\nThe poster describes how more than 400 tissue samples were screened,\nrepresenting 42 groups consisting of various cancerous and matched normal\ntissues. Of the samples screened, only lung adenocarcinoma tissues showed\nconsiderable staining with over 80% of the cells being recognized. The poster\nfurther highlights preliminary findings which demonstrate immunopositive\nstaining for L-DOS47 in human lung adenocarcinoma metastasized to lymph node\ntissues.\n\n\n\"These findings provide further evidence of the specific targeting nature\nof L-DOS47 for human lung adenocarcinoma in both primary and metastasized\ntissues,\" said Dr. Heman Chao. \"They are encouraging and support our ongoing\ncommitment in advancing L-DOS47 towards human clinical testing.\"\n\n\nA copy of the poster will be available on Helix's website for download\n(http://www.helixbiopharma.com).\n\n\nAbout L-DOS47\n\n\nL-DOS47 combines Helix's proprietary DOS47 new drug candidate with a\nhighly specific single domain antibody, to form a potential new targeted drug\nproduct for the treatment of adenocarcinoma of the lung, the most common form\nof cancer in the world today. L-DOS47 is thought to function by leveraging a\nnatural process in the body called the urea cycle, to produce an anti-cancer\neffect. It is based upon a naturally occurring enzyme called urease that\nessentially reverses the urea cycle by breaking down urea into metabolites\nthat include ammonia and hydroxyl ions. By doing so at the site of cancerous\ntissues in the body, L-DOS47 is believed to modify the microenvironmental\nconditions of lung cancer cells in a manner that lea...